PhRMA and BIO say Biden’s march-in pro­pos­al cre­ates un­cer­tain­ty in in­dus­try

PhRMA pres­i­dent Stephen Ubl ar­gued Thurs­day that the Biden ad­min­is­tra­tion’s new pro­pos­al on the use of march-in rights has “plant­ed the seeds of un­cer­tain­ty” around patent rights for pre­scrip­tion drugs.

Rep­re­sen­ta­tives from PhRMA and BIO, two of the largest biotech and phar­ma trade or­ga­ni­za­tions, con­demned the draft guid­ance dur­ing a me­dia call on Thurs­day, ar­gu­ing that the frame­work will harm in­no­va­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER